In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The closing price of Kyverna Therapeutics Inc (NASDAQ: KYTX) was $6.48 for the day, down -11.60% from the previous closing price of $7.33. In other words, the price has decreased by -$11.60 from its previous closing price. On the day, 2.44 million shares were traded. KYTX stock price reached its highest trading level at $7.387 during the session, while it also had its lowest trading level at $6.39.
Ratios:
Our analysis of KYTX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.16 and its Current Ratio is at 5.16. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.01.
On May 27, 2025, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $5.
On October 10, 2024, UBS started tracking the stock assigning a Buy rating and target price of $13.UBS initiated its Buy rating on October 10, 2024, with a $13 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KYTX now has a Market Capitalization of 280231936 and an Enterprise Value of 74472920.
Stock Price History:
The Beta on a monthly basis for KYTX is 3.73, which has changed by 0.6850575 over the last 52 weeks, in comparison to a change of 0.1476624 over the same period for the S&P500. Over the past 52 weeks, KYTX has reached a high of $8.45, while it has fallen to a 52-week low of $1.78. The 50-Day Moving Average of the stock is 5.37%, while the 200-Day Moving Average is calculated to be 75.21%.
Shares Statistics:
KYTX traded an average of 590.20K shares per day over the past three months and 537970 shares per day over the past ten days. A total of 43.79M shares are outstanding, with a floating share count of 21.32M. Insiders hold about 50.70% of the company’s shares, while institutions hold 24.76% stake in the company. Shares short for KYTX as of 1761868800 were 2696732 with a Short Ratio of 4.57, compared to 1759190400 on 1447317. Therefore, it implies a Short% of Shares Outstanding of 2696732 and a Short% of Float of 10.86.
Earnings Estimates
The market rating for Kyverna Therapeutics Inc (KYTX) is a result of the insights provided by 2.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.9, with high estimates of -$0.65 and low estimates of -$1.08.
Analysts are recommending an EPS of between -$3.66 and -$3.69 for the fiscal current year, implying an average EPS of -$3.67. EPS for the following year is -$3.62, with 5.0 analysts recommending between -$2.96 and -$4.21.
